In the last trading session, 3.96 million Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) shares changed hands as the company’s beta touched 0.26. With the company’s per share price at $26.39 changed hands at $0.08 or 0.30% during last session, the market valuation stood at $2.49B. RARE’s last price was a discount, traded about -128.76% off its 52-week high of $60.37. The share price had its 52-week low at $26.00, which suggests the last value was 1.48% up since then. When we look at Ultragenyx Pharmaceutical Inc’s average trading volume, we note the 10-day average is 4.18 million shares, with the 3-month average coming to 1.55 million.
Analysts gave the Ultragenyx Pharmaceutical Inc (RARE) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.21. If we narrow down to specifics, the data shows that 1 out of 16 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended RARE as a Hold, 14 felt it is a Buy and 0 rated the stock as Underweight.
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) trade information
Instantly RARE was in green as seen at the end of in last trading. With action -9.72%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -39.87%, with the 5-day performance at -9.72% in the red. However, in the 30-day time frame, Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is -29.34% down. Looking at the short shares, we see there were 6.08 million shares sold at short interest cover period of 5.87 days.
The consensus price target for the stock as assigned by Wall Street analysts is 89.5, meaning bulls need an upside of 70.51% from its current market value. According to analyst projections, RARE’s forecast low is 64 with 115 as the target high. To hit the forecast high, the stock’s price needs a -335.77% plunge from its current level, while the stock would need to soar -142.52% for it to hit the projected low.
Ultragenyx Pharmaceutical Inc (RARE) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 2.45%. The 2025 estimates are for Ultragenyx Pharmaceutical Inc earnings to increase by 16.06%, but the outlook for the next 5-year period is at 46.75% per year.
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.20% of Ultragenyx Pharmaceutical Inc shares while 98.45% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 101.70%. There are 98.45% institutions holding the Ultragenyx Pharmaceutical Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 11.2964% of the shares, roughly 9.78 million RARE shares worth $401.98 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 6.4718% or 5.6 million shares worth $230.3 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund. With 2.78 shares estimated at $73.44 million under it, the former controlled 2.94% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund held about 2.32% of the shares, roughly 2.19 shares worth around $57.8 million.
